Page last updated: 2024-12-09
methyl triclosan
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
methyl triclosan: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 627458 |
| CHEMBL ID | 2325395 |
| SCHEMBL ID | 676629 |
| MeSH ID | M0487578 |
Synonyms (38)
| Synonym |
|---|
| methyl triclosan |
| 4640-01-1 |
| 2,4-dichloro-1-(4-chloro-2-methoxyphenoxy)benzene |
| NCGC00248561-01 |
| methyltriclosan |
| 5174ur1dp5 , |
| unii-5174ur1dp5 |
| mtcs cpd |
| triclosan methyl |
| benzene, 4-chloro-1-(2,4-dichlorophenoxy)-2-methoxy- |
| dtxcid0027850 |
| NCGC00257753-01 |
| tox21_200199 |
| cas-4640-01-1 |
| dtxsid0047874 , |
| BRD-K62328564-001-01-1 |
| FT-0675460 |
| triclosan-methyl |
| 5-chloro-2-(2,4-dichlorophenoxy)anisole |
| triclosan methyl ether |
| 2,4,4'-trichloro-2'-methoxydiphenyl ether |
| triclosan-me |
| CHEMBL2325395 |
| SCHEMBL676629 |
| 4-chloro-1-(2,4-dichlorophenoxy)-2-methoxybenzene # |
| 2,4,4'-trichloro-4'-methoxydiphenyl ether |
| NLYDHBBTVWMLFD-UHFFFAOYSA-N |
| AKOS030524102 |
| triclosan-methyl, analytical standard |
| triclosan-methyl ether |
| mfcd04039700 |
| DS-19481 |
| Q1925612 |
| C75242 |
| CS-0129418 |
| HY-136441 |
| triclosan-methyl ether 100 microg/ml in acetonitrile |
| c13h9cl3o2 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Traditionally, the adverse effects of TCS and its by-products have been evaluated by examining the phenotypic output relevant to predicting acute toxicity rather than studying the perturbation of biological pathways." | ( The toxic effect of triclosan and methyl-triclosan on biological pathways revealed by metabolomics and gene expression in zebrafish embryos. Bae, S; Fu, J; Gong, Z; Tan, YXR, 2020) | 0.56 |
| " PCPs are biologically active substances that can exert an adverse effect on the ecology and food safety." | ( Occurrence and Safety Evaluation of Antimicrobial Compounds Triclosan and Triclocarban in Water and Fishes of the Multitrophic Niche of River Torsa, India. Aftabuddin, M; Bandyopadhyay, S; Das Sarkar, S; Das, BK; Kumari, K; Nag, SK; Saha, K, 2020) | 0.56 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Moreover, when the embryos were exposed to a mix of TCS and MTCS, TCS dominated the mixture's effect on biological pathways because the concentration ratio within the mixture, which mimics environmental ratio of 10 TCS : 1 MTCS, leads to high bioavailability of TCS." | ( Assessment of the effect of methyl-triclosan and its mixture with triclosan on developing zebrafish (Danio rerio) embryos using mass spectrometry-based metabolomics. Bae, S; Fu, J; Gong, Z, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (14)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 38.8104 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.7471 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| AR protein | Homo sapiens (human) | Potency | 17.9362 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743063 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 26.6051 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 8.3896 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 19.4749 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 24.7737 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 26.5303 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 27.4991 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743078; AID743080; AID743091 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 33.7401 | 0.0016 | 28.0151 | 77.1139 | AID1224895; AID1259385 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 23.8583 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 109.8440 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 52.9350 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 66.6412 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID726479 | Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite growth | 2013 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 | Novel diaryl ureas with efficacy in a mouse model of malaria. |
| AID726480 | Antimalarial activity against Plasmodium falciparum Dd2 assessed as inhibition of parasite growth | 2013 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4 | Novel diaryl ureas with efficacy in a mouse model of malaria. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (55)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (12.73) | 29.6817 |
| 2010's | 38 (69.09) | 24.3611 |
| 2020's | 10 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 55 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||